kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”10.17802/2306-1278-2022-11-4S-194-207kpccz-1284Research ArticleОНЛАЙН. АНАЛИТИЧЕСКИЙ ОБЗОР. Кардиология. Патологическая физиологияONLINE. REVIEW. Cardiology. Pathological physiologyСовременные представления о диагностической роли биомаркеров эндотелиальной дисфункции и возможностях ее коррекцииA modern view on the diagnostic role of endothelial dysfunction biomarkers and the possibilities of its correctionhttps://orcid.org/0000-0002-7384-9705ЗахарьянЕ. А.ZakharyanE. A.

Захарьян Елена Аркадьевна - кандидат медицинских наук, доцент кафедры внутренней медицины № 1.

бульвар Ленина, 5/7, Симферополь, Республика Крым, 295051

Elena A. Zakharyan - PhD, Associate Professor at the Department of Internal Medicine No. 1, Medical Academy named after S.I. Georgievsky of the V.I. Vernadsky Crimean Federal University.

5/7, Lenina Blvd., Simferopol, Crimea, 295051

https://orcid.org/0000-0003-3770-2965АгееваЕ. С.AgeevaE. S.

Агеева Елизавета Сергеевна - доктор медицинских наук,  доцент  заведующая  кафедрой  биологии.

бульвар Ленина, 5/7, Симферополь, Республика Крым, 295051

Elizaveta S. Ageeva - PhD, Associate Professor, Head of the Department of Biology, Medical Academy named after S.I. Georgievsky of the V.I. Vernadsky Crimean Federal University.

5/7, Lenina Blvd., Simferopol, Crimea, 295051

https://orcid.org/0000-0003-4946-7317ШрамкоЮ. И.ShramkoYu. I.

Шрамко Юлиана Ивановна - кандидат биологических наук, доцент кафедры общей и клинической патофизиологии.

бульвар Ленина, 5/7, Симферополь, Республика Крым, 295051

Yuliana I. Shramko - PhD, Associate Professor at the Department of General and Clinical Pathophysiology, Medical Academy named after S.I. Georgievsky of the V.I. Vernadsky Crimean Federal University.

5/7, Lenina Blvd., Simferopol, Crimea, 295051

https://orcid.org/0000-0002-6591-2719МалыйК. Д.MalyiK. D.

Малый Константин Дмитриевич - кандидат медицинских наук, доцент кафедры биохимии.

бульвар Ленина, 5/7, Симферополь, Республика Крым, 295051

Konstantin D. Malyi - PhD, Associate Professor at the Department of Biochemistry, Medical Academy named after S.I. Georgievsky of the V.I. Vernadsky Crimean Federal University.

5/7, Lenina Blvd., Simferopol, Crimea, 295051

https://orcid.org/0000-0001-8633-1166ГуртоваяА. К.GurtovayaA. K.

Гуртовая Анна Константиновна - лаборант центра коллективного пользования научным оборудованием «Молекулярная биология».

бульвар Ленина, 5/7, Симферополь, Республика Крым, 295051

Anna K. Gurtovaya - Laboratory Assistant at the  Center for the Collective Use of Scientific Equipment “Molecular Biology”, Medical Academy named after S.I. Georgievsky of the V.I. Vernadsky Crimean Federal University.

5/7, Lenina Blvd., Simferopol, Crimea, 295051

https://orcid.org/0000-0003-0734-9400ИбрагимоваР. Э.IbragimovaR. E.

Ибрагимова Регина Энверовна - студент кафедры внутренней медицины № 1.

бульвар Ленина, 5/7, Симферополь, Республика Крым, 295051

Regina E. Ibragimova - Student at the Department of Internal Medicine No. 1, Medical Academy named after S.I. Georgievsky of the V.I. Vernadsky Crimean Federal University.

5/7, Lenina Blvd., Simferopol, Crimea, 295051

irregina.2000@mail.ruМедицинская академия имени С.И. Георгиевского Крымского федерального университета имени В.И. ВернадскогоРоссияMedical Academy named after S.I. Georgievsky of the V.I. Vernadsky Crimean Federal UniversityRussian Federation202204022023114Sприложение194207Copyright © Захарьян Е.А., Агеева Е.С., Шрамко Ю.И., Малый К.Д., Гуртовая А.К., Ибрагимова Р.Э., 20232023Захарьян Е.А., Агеева Е.С., Шрамко Ю.И., Малый К.Д., Гуртовая А.К., Ибрагимова Р.Э.Zakharyan E.A., Ageeva E.S., Shramko Y.I., Malyi K.D., Gurtovaya A.K., Ibragimova R.E.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/1284Основные положения

Основные положения. Статья представляет собой обзор актуальных литературных данных, посвященных изучению диагностической роли биомаркеров эндотелиальной дисфункции. В обзоре освещены характеристики основных показателей, их значение при различной патологии, а также представлены возможные терапевтические стратегии предотвращения эндотелиальной дисфункции.

Резюме

Резюме. Эндотелиальная дисфункция является характерной чертой каждого этапа сердечно-сосудистого континуума – ряда событий от гипертонии до развития атеросклероза и ишемической болезни сердца, образования тромбов, инфаркта миокарда и сердечной недостаточности. В связи с выдающейся ролью эндотелиальной дисфункции в патогенезе многих сосудистых заболеваний, она представляет собой значимую терапевтическую мишень. Важно отметить, что циркулирующие биомаркеры активации и повреждения эндотелия характеризуют тяжесть заболевания и могут быть использованы для оценки эффективности лечения и последующего прогноза. Цель данного обзора – представить современные данные о функции эндотелия, ее клинической значимости в сердечно-сосудистом континууме, последних достижениях молекулярной и клеточной биологии и их значении для клинической практики с акцентом на новых методах терапевтической коррекции эндотелиальной дисфункции.

Highlights

Highlights. The article presents a review of literature data on the diagnostic role of endothelial dysfunction biomarkers. The review provides an overview of the main indicators, their significance in various pathologies, and presents possible therapeutic strategies for preventing endothelial dysfunction.

Abstract

Abstract. Endothelial dysfunction is a characteristic feature of each stage of the cardiovascular continuum – a series of events from hypertension to the development of atherosclerosis and coronary heart disease, thrombus formation, myocardial infarction, and heart failure. Due to the prominent role of endothelial dysfunction in the pathogenesis of many vascular diseases, it is a significant therapeutic target. It is important to note that circulating markers of endothelial activation and damage characterize the severity of the disease and can be used to evaluate the efficacy of treatment and subsequent prognosis. The purpose of this review is to provide up–to-date data on endothelial function, discussing its clinical relevance in the cardiovascular continuum, the latest insights in molecular and cellular biology, and their implications for clinical practice, with a focus on new methods of therapeutic approaches for correcting endothelial dysfunction.

ЭндотелийБиомаркерыЭндоглинЭндоканСосудистый эндотелиальный фактор ростаМолекулы клеточной адгезииМикрочастицыEndotheliumBiomarkersEndoglinEndoсanVascular endothelial growth factorCell adhesion moleculesMicroparticlesИсследование выполнено за счет гранта Российского научного фонда № 22-25-20053, https://rscf.ru/project/22-25-20053/ReferencesAlexander Y., Osto E., Schmidt-Trucksäss A., Shechter M., Trifunovic D., Duncker D.J., Aboyans V., Bäck M., Badimon L., Cosentino F., De Carlo M., Dorobantu M., Harrison D.G., Guzik T.J., Hoefer I., Morris P.D., Norata G.D., Suades R., Taddei S., Vilahur G., Waltenberger J., Weber C., Wilkinson F., Bochaton-Piallat M.L., Evans P.C. Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. Cardiovasc Res. 2021;117(1):29-42. doi: 10.1093/cvr/cvaa085.Alexander Y., Osto E., Schmidt-Trucksäss A., Shechter M., Trifunovic D., Duncker D.J., Aboyans V., Bäck M., Badimon L., Cosentino F., De Carlo M., Dorobantu M., Harrison D.G., Guzik T.J., Hoefer I., Morris P.D., Norata G.D., Suades R., Taddei S., Vilahur G., Waltenberger J., Weber C., Wilkinson F., Bochaton-Piallat M.L., Evans P.C. Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. Cardiovasc Res. 2021;117(1):29-42. doi: 10.1093/cvr/cvaa085.Leite A.R., Borges-Canha M., Cardoso R., Neves J.S., Castro-Ferreira R., Leite-Moreira A. Novel Biomarkers for Evaluation of Endothelial Dysfunction. Angiology. 2020; 71(5): 397-410. doi:10.1177/0003319720903586.Leite A.R., Borges-Canha M., Cardoso R., Neves J.S., Castro-Ferreira R., Leite-Moreira A. Novel Biomarkers for Evaluation of Endothelial Dysfunction. Angiology. 2020; 71(5): 397-410. doi:10.1177/0003319720903586.Medina-Leyte D.J., Zepeda-García O., Domínguez-Pérez M., González-Garrido A., Villarreal-Molina T., Jacobo-Albavera L. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. International journal of molecular sciences. 2021; 22(8): 3850. doi:10.3390/ijms22083850.Medina-Leyte D.J., Zepeda-García O., Domínguez-Pérez M., González-Garrido A., Villarreal-Molina T., Jacobo-Albavera L. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. International journal of molecular sciences. 2021; 22(8): 3850. doi:10.3390/ijms22083850.Xu S., Ilyas I., Little P.J., Li H., Kamato D., Zheng X., Luo S., Li Z., Liu P., Han J., Harding I.C., Ebong E.E., Cameron S.J., Stewart A.G., Weng J. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Reviews. 2021; 73(3): 924-967. doi:10.1124/pharmrev.120.000096.Xu S., Ilyas I., Little P.J., Li H., Kamato D., Zheng X., Luo S., Li Z., Liu P., Han J., Harding I.C., Ebong E.E., Cameron S.J., Stewart A.G., Weng J. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Reviews. 2021; 73(3): 924-967. doi:10.1124/pharmrev.120.000096.Incalza M.A., D'Oria R., Natalicchio A., Perrini S., Laviola L., Giorgino F.. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascular pharmacology. 2018; 100: 1-19. doi:10.1016/j.vph.2017.05.005.Incalza M.A., D'Oria R., Natalicchio A., Perrini S., Laviola L., Giorgino F.. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascular pharmacology. 2018; 100: 1-19. doi:10.1016/j.vph.2017.05.005.Balta S. Endothelial Dysfunction and Inflammatory Markers of Vascular Disease. Current Vascular Pharmacology. 2021;19(3):243-249. doi:10.2174/1570161118666200421142542.Balta S. Endothelial Dysfunction and Inflammatory Markers of Vascular Disease. Current Vascular Pharmacology. 2021;19(3):243-249. doi:10.2174/1570161118666200421142542.Liang S., Zhang J., Ning R., Du Z., Liu J., Batibawa J.W., Duan J., Sun Z.. The critical role of endothelial function in fine particulate matter-induced atherosclerosis. Particle and Fibre Toxicology. 2020; 17(1): 61. doi:10.1186/s12989-020-00391-x.Liang S., Zhang J., Ning R., Du Z., Liu J., Batibawa J.W., Duan J., Sun Z.. The critical role of endothelial function in fine particulate matter-induced atherosclerosis. Particle and Fibre Toxicology. 2020; 17(1): 61. doi:10.1186/s12989-020-00391-x.Lugo-Gavidia L.M., Burger D., Matthews V.B., Nolde J.M., Galindo Kiuchi M., Carnagarin R., Kannenkeril D., Chan J., Joyson A., Herat L.Y., Azzam O., Schlaich M.P. Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension. 2021; 77(6): 1825-1844. doi:10.1161/HYPERTENSIONAHA.121.16975.Lugo-Gavidia L.M., Burger D., Matthews V.B., Nolde J.M., Galindo Kiuchi M., Carnagarin R., Kannenkeril D., Chan J., Joyson A., Herat L.Y., Azzam O., Schlaich M.P. Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension. 2021; 77(6): 1825-1844. doi:10.1161/HYPERTENSIONAHA.121.16975.Самолюк М.О., Григорьева Н. Ю. Оценка эндотелиальной дисфункции и возможности ее коррекции на современном этапе у больных сердечно-сосудистыми заболеваниями. Кардиология. 2019; 59 (3): 4-9. doi:10.18087/cardio.2524.Samolyuk M.O., Grigoryeva N.Yu. Evaluation of endothelial dysfunction and possibilities of its correction at the present stage in patients with cardiovascular diseases. Cardiology. 2019; 59 (3): 4-9. doi:10.18087/cardio.2524. (In Russian)Никитин Ю.П., Николаев К.Ю., Рагино Ю.И., Малютина С.К., Журавская Э.Я., Полонская Я.В. и др. Эндотелиальная дисфункция, гипертония, атеросклероз. Новосибирск; 2014Nikitin Y.P., Nikolaev K.Y., Ragino Y.I., Malyutina S.K., Zhuravskaya E.Ya., Polonskaya Ya.V. et al. Endothelial dysfunction, hypertension, and atherosclerosis. Novosibirsk; 2014 (In Russian)Стрюкова Е. В., Рагино Ю. И., Максимов В. Н. Биохимические маркеры эндотелиальной дисфункции и гемостаза при атеросклерозе и гены, ответственные за их регуляцию. Атеросклероз. 2017; 13 (1): 49-56.Strukova E. V., Ragino Y. I., Maksimov V. N. Biochemical markers of endothelial dysfunction and hemostasis in atherosclerosis and the genes responsible for their regulation. Atherosclerosis. 2017; 13 (1): 49-56.(In Russian)Dowsett L., Higgins E., Alanazi S., Alshuwayer N.A., Leiper F.C., Leiper J. ADMA: A Key Player in the Relationship between Vascular Dysfunction and Inflammation in Atherosclerosis. Journal of Clinical Medicine. 2020; 9 (9): 3026. doi:10.3390/jcm9093026.Dowsett L., Higgins E., Alanazi S., Alshuwayer N.A., Leiper F.C., Leiper J. ADMA: A Key Player in the Relationship between Vascular Dysfunction and Inflammation in Atherosclerosis. Journal of Clinical Medicine. 2020; 9 (9): 3026. doi:10.3390/jcm9093026.Jud P., Hafner F., Verheyen N., Meinitzer A., Gary T., Brodmann M., Seinost G., Hackl G. Homoarginine/ADMA ratio and homoarginine/SDMA ratio as independent predictors of cardiovascular mortality and cardiovascular events in lower extremity arterial disease. Scientific Reports. 2018; 8: 14197.Jud P., Hafner F., Verheyen N., Meinitzer A., Gary T., Brodmann M., Seinost G., Hackl G. Homoarginine/ADMA ratio and homoarginine/SDMA ratio as independent predictors of cardiovascular mortality and cardiovascular events in lower extremity arterial disease. Scientific Reports. 2018; 8: 14197.Liu Y., Paauwe M., Nixon A.B., Hawinkels L.J.A.C. Endoglin Targeting: Lessons Learned and Questions That Remain. International Journal of Molecular Sciences. 2020; 22(1):147. doi:10.3390/ijms22010147.Liu Y., Paauwe M., Nixon A.B., Hawinkels L.J.A.C. Endoglin Targeting: Lessons Learned and Questions That Remain. International Journal of Molecular Sciences. 2020; 22(1):147. doi:10.3390/ijms22010147.Shyu K.G. The Role of Endoglin in Myocardial Fibrosis. Acta Cardiologica Sinica. 2017;33(5):461-467. doi:10.6515/acs20170221b.Shyu K.G. The Role of Endoglin in Myocardial Fibrosis. Acta Cardiologica Sinica. 2017;33(5):461-467. doi:10.6515/acs20170221b.Rossi E., Bernabeu C., Smadja D.M. Endoglin as an Adhesion Molecule in Mature and Progenitor Endothelial Cells: A Function Beyond TGF-β. Front Med (Lausanne). 2019;6:10. doi: 10.3389/fmed.2019.00010.Rossi E., Bernabeu C., Smadja D.M. Endoglin as an Adhesion Molecule in Mature and Progenitor Endothelial Cells: A Function Beyond TGF-β. Front Med (Lausanne). 2019;6:10. doi: 10.3389/fmed.2019.00010.Vicen M., Igreja Sá I.C., Tripská K., Vitverová B., Najmanová I., Eissazadeh S., Micuda S., Nachtigal P.. Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome. Cellular and Molecular Life Sciences. 2021;78(6):2405-2418. doi:10.1007/s00018-020-03701-w.Vicen M., Igreja Sá I.C., Tripská K., Vitverová B., Najmanová I., Eissazadeh S., Micuda S., Nachtigal P.. Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome. Cellular and Molecular Life Sciences. 2021;78(6):2405-2418. doi:10.1007/s00018-020-03701-w.Margioula-Siarkou G., Margioula-Siarkou C., Petousis S., Margaritis K., Vavoulidis E., Gullo G., Alexandratou M., Dinas K., Sotiriadis A., Mavromatidis G. The role of endoglin and its soluble form in pathogenesis of preeclampsia. Molecular and Cellular Biochemistry. 2022; 477(2): 479-491. doi:10.1007/s11010-021-04294-z.Margioula-Siarkou G., Margioula-Siarkou C., Petousis S., Margaritis K., Vavoulidis E., Gullo G., Alexandratou M., Dinas K., Sotiriadis A., Mavromatidis G. The role of endoglin and its soluble form in pathogenesis of preeclampsia. Molecular and Cellular Biochemistry. 2022; 477(2): 479-491. doi:10.1007/s11010-021-04294-z.Zhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Reviews in Cardiovascular Medicine. 2022; 23(2): 73. doi:10.31083/j.rcm2302073.Zhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Reviews in Cardiovascular Medicine. 2022; 23(2): 73. doi:10.31083/j.rcm2302073.Balta S., Balta I., Mikhailidis D.P. Endocan: a new marker of endothelial function. Current Opinion in Cardiology. 2021; 36(4): 462-468. doi:10.1097/HCO.0000000000000867.Balta S., Balta I., Mikhailidis D.P. Endocan: a new marker of endothelial function. Current Opinion in Cardiology. 2021; 36(4): 462-468. doi:10.1097/HCO.0000000000000867.Hsiao S.Y., Kung C.T., Tsai N.W., Su C.M., Huang C.C., Lai Y.R., Wang H.C., Cheng B.C., Su Y.J., Lin W.C., Chiang Y.F., Lu C.H. Concentration and value of endocan on outcome in adult patients after severe sepsis. Clin Chim Acta. 2018;483:275-280. doi: 10.1016/j.cca.2018.05.007..Hsiao S.Y., Kung C.T., Tsai N.W., Su C.M., Huang C.C., Lai Y.R., Wang H.C., Cheng B.C., Su Y.J., Lin W.C., Chiang Y.F., Lu C.H. Concentration and value of endocan on outcome in adult patients after severe sepsis. Clin Chim Acta. 2018;483:275-280. doi: 10.1016/j.cca.2018.05.007.Kundi H., Balun A., Cicekcioglu H., Karayigit O., Topcuoglu C., Kilinckaya M.F., Kiziltunc E., Cetin M., Ornek E. Admission endocan level may be a useful predictor for in-hospital mortality and coronary severity index in patients with ST-segment elevation myocardial infarction. Angiology. 2017; 68: 46-51. doi:10.1177/0003319716646932.Kundi H., Balun A., Cicekcioglu H., Karayigit O., Topcuoglu C., Kilinckaya M.F., Kiziltunc E., Cetin M., Ornek E. Admission endocan level may be a useful predictor for in-hospital mortality and coronary severity index in patients with ST-segment elevation myocardial infarction. Angiology. 2017; 68: 46-51. doi:10.1177/0003319716646932.Степанова Т. В., Иванов А.Н., Терешкина Н.Е., Попыхова Э.Б., Лагутина Д.Д. Маркеры эндотелиальной дисфункции: патогенетическая роль и диагностическое значение (обзор литературы). Клиническая лабораторная диагностика.2019; 64(1): 34-41. doi:10.18821/0869-2084-2019-64-1-34-41.Stepanova T.V., Ivanov A.N., Tereshkina N.E., Popyhova E.B., Lagutina D.D. Markers of endothelial dysfunction: pathogenetic role and diagnostic significance (literature review). Clinical Laboratory Diagnostics.2019; 64(1): 34-41. doi:10.18821/0869-2084-2019-64-1-34-41. (In Russian)Zhou Y., Zhu X., Cui H., Shi J., Yuan G., Shi S., Hu Y. The Role of the VEGF Family in Coronary Heart Disease. Frontiers in cardiovascular medicine. 2021; 8: 738325. doi:10.3389/fcvm.2021.738325.Zhou Y., Zhu X., Cui H., Shi J., Yuan G., Shi S., Hu Y. The Role of the VEGF Family in Coronary Heart Disease. Frontiers in cardiovascular medicine. 2021; 8: 738325. doi:10.3389/fcvm.2021.738325.Dabravolski S.A., Khotina V.A., Omelchenko A.V., Kalmykov V.A., Orekhov A.N. The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets. International Journal of Molecular Sciences. 2022; 23(2): 931. doi:10.3390/ijms23020931.Dabravolski S.A., Khotina V.A., Omelchenko A.V., Kalmykov V.A., Orekhov A.N. The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets. International Journal of Molecular Sciences. 2022; 23(2): 931. doi:10.3390/ijms23020931.Garcia R., Bouleti C., Sirol M., Logeart D., Monnot C., Ardidie-Robouant C., Caligiuri G., Mercadier J.J., Germain S. VEGF-A plasma levels are associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology. 2019; 291: 19-24. doi:10.1016/j.ijcard.2019.02.067.Garcia R., Bouleti C., Sirol M., Logeart D., Monnot C., Ardidie-Robouant C., Caligiuri G., Mercadier J.J., Germain S. VEGF-A plasma levels are associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology. 2019; 291: 19-24. doi:10.1016/j.ijcard.2019.02.067.Попков В.М., Понукалин А.Н., Захарова Н.Б. Сосудистый эндотелиальный фактор роста в диагностике метастазов мышечно-инвазивного рака мочевого пузыря. Онкоурология. 2016; 12(2): 53-57. doi:10.17650/1726-9776-2016-12-2-53-57.Popkov V.M., Ponukalin A.N., Zakharova N.B. Vascular endothelial growth factor in diagnostics of metastases of a muscleinvasive bladder cancer. Onkourologiya. 2016; 12(2): 53– 57. doi: 10.17650/1726-9776-2016-12-2-53-57 ( In Russian)Park J.Y., Lee J.Y., Lee Y.Y., Shim S.H., Suh D.H., Kim J.W. Major clinical research advances in gynecologic cancer in 2021. Journal of Gynecologic Oncology. 2022; 33(2): 43. doi:10.3802/jgo.2022.33.e43.Park J.Y., Lee J.Y., Lee Y.Y., Shim S.H., Suh D.H., Kim J.W. Major clinical research advances in gynecologic cancer in 2021. Journal of Gynecologic Oncology. 2022; 33(2): 43. doi:10.3802/jgo.2022.33.e43.Flower V.A., Barratt S.L., Ward S., Pauling J.D. The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis. Current rheumatology reviews. 2019; 15(2): 99-109. doi:10.2174/1573397114666180809121005.Flower V.A., Barratt S.L., Ward S., Pauling J.D. The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis. Current rheumatology reviews. 2019; 15(2): 99-109. doi:10.2174/1573397114666180809121005.Moreira F. R. C., de Oliveira T.A., Ramos N.E., Abreu M.A.D., Simões E Silva A.C. The role of renin angiotensin system in the pathophysiology of rheumatoid arthritis. Molecular Biology Reports. 2021; 48(9): 6619-6629. doi:10.1007/s11033-021-06672-8.Moreira F. R. C., de Oliveira T.A., Ramos N.E., Abreu M.A.D., Simões E Silva A.C. The role of renin angiotensin system in the pathophysiology of rheumatoid arthritis. Molecular Biology Reports. 2021; 48(9): 6619-6629. doi:10.1007/s11033-021-06672-8.Troncoso M. F., Ortiz-Quintero J., Garrido-Moreno V., Sanhueza-Olivares F., Guerrero-Moncayo A., Chiong M., Castro P.F., García L., Gabrielli L., Corbalán R., Garrido-Olivares L., Lavandero S. VCAM-1 as a predictor biomarker in cardiovascular disease. Biochimica et Biophysica Acta (BBA). Molecular Basis of Disease. 2021; 1867(9): 166170. doi:10.1016/j.bbadis.2021.166170.Troncoso M. F., Ortiz-Quintero J., Garrido-Moreno V., Sanhueza-Olivares F., Guerrero-Moncayo A., Chiong M., Castro P.F., García L., Gabrielli L., Corbalán R., Garrido-Olivares L., Lavandero S. VCAM-1 as a predictor biomarker in cardiovascular disease. Biochimica et Biophysica Acta (BBA). Molecular Basis of Disease. 2021; 1867(9): 166170. doi:10.1016/j.bbadis.2021.166170.Белокопытова И.С., Москалец О.В., Палеев Ф.Н., Зотова О.В. Диагностическая ценность адгезивных молекул sICAM-1 и sVCAM-1 при ишемической болезни сердца. Атеросклероз и дислипидемии. 2013; 4: 62-5.Belokopytova I.S., Moskaletz O.V., Paleev F.N., Zotova O.V. The diagnostic value of adhesive molecules sICAM-1 and sVCAM-1 in ischemic heart disease. Ateroskleroz i dislipidemii. 2013; 4: 62–5. (In Russian)Chen Y.H., Lightman S., Eskandarpour M., Calder V.L. Adhesion Molecule Targeted Therapy for Non-Infectious Uveitis. International Journal of Molecular Sciences. 2022;23(1):503. doi:10.3390/ijms23010503.Chen Y.H., Lightman S., Eskandarpour M., Calder V.L. Adhesion Molecule Targeted Therapy for Non-Infectious Uveitis. International Journal of Molecular Sciences. 2022;23(1):503. doi:10.3390/ijms23010503.Oates J.C., Russell D.L., Van Beusecum J.P. Endothelial cells: potential novel regulators of renal inflammation. American Journal of Physiology-Renal Physiology. 2022; 322(3): 309-F321. doi:10.1152/ajprenal.00371.2021.Oates J.C., Russell D.L., Van Beusecum J.P. Endothelial cells: potential novel regulators of renal inflammation. American Journal of Physiology-Renal Physiology. 2022; 322(3): 309-F321. doi:10.1152/ajprenal.00371.2021.Kong D.H., Kim Y.K., Kim M.R., Jang J.H., Lee S. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. International journal of molecular sciences. 2018; 19(4): 1057. doi:10.3390/ijms19041057.Kong D.H., Kim Y.K., Kim M.R., Jang J.H., Lee S. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. International journal of molecular sciences. 2018; 19(4): 1057. doi:10.3390/ijms19041057.Fatahi S., Daneshzad E., Lotfi K., Azadbakht L. The effects of almond consumption on inflammatory biomarkers in adults: A systematic review and meta-analysis of randomized clinical trials. Advances in Nutrition. 2021:158. doi:10.1093/advances/nmab158.Fatahi S., Daneshzad E., Lotfi K., Azadbakht L. The effects of almond consumption on inflammatory biomarkers in adults: A systematic review and meta-analysis of randomized clinical trials. Advances in Nutrition. 2021:158. doi:10.1093/advances/nmab158.Chen Y.T., Yuan H.X., Ou Z.J., Ou J.S. Microparticles (Exosomes) and Atherosclerosis. Current atherosclerosis reports. 2020; 22(6): 23. doi:10.1007/s11883-020-00841-z.Chen Y.T., Yuan H.X., Ou Z.J., Ou J.S. Microparticles (Exosomes) and Atherosclerosis. Current atherosclerosis reports. 2020; 22(6): 23. doi:10.1007/s11883-020-00841-z.Lugo-Gavidia L. M., Burger D., Matthews V.B., Nolde J.M., Galindo Kiuchi M., Carnagarin R., Kannenkeril D., Chan J., Joyson A., Herat L.Y., Azzam O., Schlaich M.P. Role of microparticles in cardiovascular disease: implications for endothelial dysfunction, thrombosis, and inflammation. Hypertension. 2021; 77(6): 1825-1844. doi:10.1161/HYPERTENSIONAHA.121.16975.Lugo-Gavidia L. M., Burger D., Matthews V.B., Nolde J.M., Galindo Kiuchi M., Carnagarin R., Kannenkeril D., Chan J., Joyson A., Herat L.Y., Azzam O., Schlaich M.P. Role of microparticles in cardiovascular disease: implications for endothelial dysfunction, thrombosis, and inflammation. Hypertension. 2021; 77(6): 1825-1844. doi:10.1161/HYPERTENSIONAHA.121.16975.Pernomian L., Moreira J.D., Gomes M.S. In the View of Endothelial Microparticles: Novel Perspectives for Diagnostic and Pharmacological Management of Cardiovascular Risk during Diabetes Distress. Journal of Diabetes Research. 2018; 2018. doi:10.1155/2018/9685205.Pernomian L., Moreira J.D., Gomes M.S. In the View of Endothelial Microparticles: Novel Perspectives for Diagnostic and Pharmacological Management of Cardiovascular Risk during Diabetes Distress. Journal of Diabetes Research. 2018; 2018. doi:10.1155/2018/9685205.Rogula S., Gąsecka A., Filipiak K.J. Macroscopic role of microparticles in cardiovascular disease. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego.2020; 49(286): 255-259.Rogula S., Gąsecka A., Filipiak K.J. Macroscopic role of microparticles in cardiovascular disease. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego.2020; 49(286): 255-259.Cooper S., Teoh H., Campeau M.A., Verma S., Leask R.L. Empagliflozin restores the integrity of the endothelial glycocalyx in vitro. Molecular and Cellular Biochemistry. 2019; 459: 121–130. doi: 10.1007/s11010-019-03555-2Cooper S., Teoh H., Campeau M.A., Verma S., Leask R.L. Empagliflozin restores the integrity of the endothelial glycocalyx in vitro. Molecular and Cellular Biochemistry. 2019; 459: 121–130. doi: 10.1007/s11010-019-03555-2Aini K., Fukuda D., Tanaka K., Higashikuni Y., Hirata Y., Yagi S., Kusunose K., Yamada H., Soeki T., Sata M. Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice. International heart journal. 2019; 60: 1421–1429. doi: 10.1536/ihj.19-117.Aini K., Fukuda D., Tanaka K., Higashikuni Y., Hirata Y., Yagi S., Kusunose K., Yamada H., Soeki T., Sata M. Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice. International heart journal. 2019; 60: 1421–1429. doi: 10.1536/ihj.19-117.Sardu C., Paolisso P., Sacra C., Mauro C., Minicucci F., Portoghese M., Rizzo M.R., Barbieri M., Sasso F.C., D'Onofrio N., Balestrieri M.L., Calabrò P., Paolisso G., Marfella R. Effects of metformin therapy on coronary endothelial dysfunction in patients with prediabetes with stable angina and nonobstructive coronary artery stenosis: the CODYCE multicenter prospective study. Diabetes Care. 2019; 42(10): 1946-1955. doi: 10.2337/dc18-2356.Sardu C., Paolisso P., Sacra C., Mauro C., Minicucci F., Portoghese M., Rizzo M.R., Barbieri M., Sasso F.C., D'Onofrio N., Balestrieri M.L., Calabrò P., Paolisso G., Marfella R. Effects of metformin therapy on coronary endothelial dysfunction in patients with prediabetes with stable angina and nonobstructive coronary artery stenosis: the CODYCE multicenter prospective study. Diabetes Care. 2019; 42(10): 1946-1955. doi: 10.2337/dc18-2356.Becher T., Schulze T.J., Schmitt M., Trinkmann F., El-Battrawy I., Akin I., Kälsch T., Borggrefe M., Stach K. Ezetimibe inhibits platelet activation and uPAR expression on endothelial cells. International journal of cardiology. 2017; 227: 858–862. doi:10.1016/j.ijcard.2016.09.122.Becher T., Schulze T.J., Schmitt M., Trinkmann F., El-Battrawy I., Akin I., Kälsch T., Borggrefe M., Stach K. Ezetimibe inhibits platelet activation and uPAR expression on endothelial cells. International journal of cardiology. 2017; 227: 858–862. doi:10.1016/j.ijcard.2016.09.122.Bacchiega B. C., Bacchiega A.B., Usnayo M.J., Bedirian R., Singh G., Pinheiro G.D. Interleukin 6 inhibition and coronary artery disease in a High‐Risk population: a prospective Community‐ Based clinical study. Journal of the American Heart Association. 2017; 6(3): e005038. doi:10.1161/JAHA.116.005038.Bacchiega B. C., Bacchiega A.B., Usnayo M.J., Bedirian R., Singh G., Pinheiro G.D. Interleukin 6 inhibition and coronary artery disease in a High‐Risk population: a prospective Community‐ Based clinical study. Journal of the American Heart Association. 2017; 6(3): e005038. doi:10.1161/JAHA.116.005038.Ikonomidis I., Pavlidis G., Katsimbri P., Lambadiari V., Parissis J., Andreadou I., Tsoumani M., Boumpas D., Kouretas D., Iliodromitis E. Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19. Food and Chemical Toxicology. 2020; 145: 111694. doi:10.1016/j.fct.2020.111694.Ikonomidis I., Pavlidis G., Katsimbri P., Lambadiari V., Parissis J., Andreadou I., Tsoumani M., Boumpas D., Kouretas D., Iliodromitis E. Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19. Food and Chemical Toxicology. 2020; 145: 111694. doi:10.1016/j.fct.2020.111694.Yang X., Wan M., Cheng Z., Wang Z., Wu Q. Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells. Artificial Cells, Nanomedicine, and Biotechnology. 2019; 47(1): 2775-2782. doi:10.1080/21691401.2019.1573740.Yang X., Wan M., Cheng Z., Wang Z., Wu Q. Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells. Artificial Cells, Nanomedicine, and Biotechnology. 2019; 47(1): 2775-2782. doi:10.1080/21691401.2 019.1573740.Ashry N. A., Abdеlaziz R. R., Suddеk G. M. The potential effect of imatinib against hypercholesterolemia induced atherosclerosis, endothelial dysfunction and hepatic injury in rabbits. Life sciences. 2020; 243: 117275. doi:10.1016/j.lfs.2020.117275.Ashry N. A., Abdеlaziz R. R., Suddеk G. M. The potential effect of imatinib against hypercholesterolemia induced atherosclerosis, endothelial dysfunction and hepatic injury in rabbits. Life sciences. 2020; 243: 117275. doi:10.1016/j.lfs.2020.117275.Zhou X., Cai J., Liu W., Wu X., Gao C. Cysteinyl leukotriene receptor type 1 (CysLT1R) antagonist zafirlukast protects against TNF-α-induced endothelial inflammation. Biomedicine & Pharmacotherapy. 2019; 111: 452-459. doi:10.1016/j.biopha.2018.12.064.Zhou X., Cai J., Liu W., Wu X., Gao C. Cysteinyl leukotriene receptor type 1 (CysLT1R) antagonist zafirlukast protects against TNF-α-induced endothelial inflammation. Biomedicine & Pharmacotherapy. 2019; 111: 452-459. doi:10.1016/j.biopha.2018.12.064.Pang J., Hu P., Wang J., Jiang J., Lai J. Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT/JNK and NF-κB signaling pathways. Molecular Medicine Reports. 2019; 19(6): 5291-5300. doi:10.3892/mmr.2019.10211.Pang J., Hu P., Wang J., Jiang J., Lai J. Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT/JNK and NF-κB signaling pathways. Molecular Medicine Reports. 2019; 19(6): 5291-5300. doi:10.3892/mmr.2019.10211.Campo G., Vieceli Dalla Sega F., Pavasini R., Aquila G., Gallo F., Fortini F., Tonet E., Cimaglia P., Del Franco A., Pestelli G., Pecoraro A., Contoli M., Balla C., Biscaglia S., Rizzo P., Ferrari R. Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thrombosis and haemostasis. 2017; 117(6): 1208-1216. doi:10.1160/TH16-12-0973.Campo G., Vieceli Dalla Sega F., Pavasini R., Aquila G., Gallo F., Fortini F., Tonet E., Cimaglia P., Del Franco A., Pestelli G., Pecoraro A., Contoli M., Balla C., Biscaglia S., Rizzo P., Ferrari R. Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thrombosis and haemostasis. 2017; 117(6): 1208-1216. doi:10.1160/TH16-12-0973.Aquila G., Vieceli Dalla Sega F., Marracino L., Pavasini R., Cardelli L.S., Piredda A., Scoccia A., Martino V., Fortini F., Bononi I., Martini F., Manfrini M., Pannuti A., Ferrari R., Rizzo P., Campo G. Ticagrelor increases SIRT1 and HES1 mRNA levels in peripheral blood cells from patients with stable coronary artery disease and chronic obstructive pulmonary disease. International journal of molecular sciences. 2020; 21(5): 1576. doi:10.3390/ijms21051576.Aquila G., Vieceli Dalla Sega F., Marracino L., Pavasini R., Cardelli L.S., Piredda A., Scoccia A., Martino V., Fortini F., Bononi I., Martini F., Manfrini M., Pannuti A., Ferrari R., Rizzo P., Campo G. Ticagrelor increases SIRT1 and HES1 mRNA levels in peripheral blood cells from patients with stable coronary artery disease and chronic obstructive pulmonary disease. International journal of molecular sciences. 2020; 21(5): 1576. doi:10.3390/ijms21051576.Vianello F., Sambado L., Goss A., Fabris F., Prandoni P. Dabigatran antagonizes growth, cell‐cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines. Cancer Medicine. 2016; 5(10): 2886-2898. doi:10.1002/cam4.857Vianello F., Sambado L., Goss A., Fabris F., Prandoni P. Dabigatran antagonizes growth, cell‐cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines. Cancer Medicine. 2016; 5(10): 2886-2898. doi:10.1002/cam4.857Pedralli M.L., Marschner R.A., Kollet D.P., Neto S.G., Eibel B., Tanaka H., Lehnen A.M. Different exercise training modalities produce similar endothelial function improvements in individuals with prehypertension or hypertension: A randomized clinical trial. Scientific reports. 2020; doi: 10: 1–9. 10.1038/s41598-020-64365-xPedralli M.L., Marschner R.A., Kollet D.P., Neto S.G., Eibel B., Tanaka H., Lehnen A.M. Different exercise training modalities produce similar endothelial function improvements in individuals with prehypertension or hypertension: A randomized clinical trial. Scientific reports. 2020; doi: 10: 1–9. 10.1038/s41598-020-64365-xFatima K., Rashid A.M., Memon U.A.A., Fatima S.S., Javaid S.S., Shahid O., Zehri F., Obaid M.A., Ahmad M., Almas T., Minhas A.M.K. Mediterranean Diet and its Effect on Endothelial Function: A Meta-analysis and Systematic Review. Irish Journal of Medical Science. 2022: 1-9. doi:10.1007/s11845-022-02944-9.Fatima K., Rashid A.M., Memon U.A.A., Fatima S.S., Javaid S.S., Shahid O., Zehri F., Obaid M.A., Ahmad M., Almas T., Minhas A.M.K. Mediterranean Diet and its Effect on Endothelial Function: A Meta-analysis and Systematic Review. Irish Journal of Medical Science. 2022: 1-9. doi:10.1007/s11845-022-02944-9.Golbidi S., Edvinsson L., Laher I. Smoking and Endothelial Dysfunction. Current Vascular Pharmacology. 2020;18(1):1-11. doi: 10.2174/1573403X14666180913120015.Golbidi S., Edvinsson L., Laher I. Smoking and Endothelial Dysfunction. Current Vascular Pharmacology. 2020;18(1):1-11. doi: 10.2174/1573403X14666180913120015.

The authors declare that there are no conflicts of interest present.